Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2007 2
2008 1
2009 1
2010 4
2011 2
2013 1
2015 2
2017 3
2018 1
2019 1
2020 1
2021 1
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Renal parenchymal hypertension: relevant new aspects.
Vachek J, Zakiyanov O, Oulehle K, Ciferská H, Tesař V. Vachek J, et al. Among authors: ciferska h. Vnitr Lek. 2021 Winter;67(8):479-484. Vnitr Lek. 2021. PMID: 35459368 English.
Differential diagnosis of back pain.
Ciferská H, Vachek J. Ciferská H, et al. Vnitr Lek. 2022 Fall;68(5):332-341. doi: 10.36290/vnl.2022.068. Vnitr Lek. 2022. PMID: 36283825 English.
[Merkel cell skin carcinoma].
Krejcí K, Zadrazil J, Tichý T, Horák P, Ciferská H, Hodulová M, Zezulová M, Zlevorová M. Krejcí K, et al. Among authors: ciferska h. Klin Onkol. 2010;23(4):210-7. Klin Onkol. 2010. PMID: 20806818 Review. Czech.
VEXAS syndrome: a report of three cases.
Ciferska H, Gregová M, Klein M, Šenolt L, Soukupová Maaloufová J, Pavelka K, Mann H. Ciferska H, et al. Clin Exp Rheumatol. 2022 Jul;40(7):1449. doi: 10.55563/clinexprheumatol/3z07e9. Epub 2022 Feb 12. Clin Exp Rheumatol. 2022. PMID: 35238760 Free article. No abstract available.
Complement system in SLE as a target for antibodies.
Horak P, Skacelova M, Zadrazil J, Smrzova A, Krejcí K, Ciferska H, Hermanova Z. Horak P, et al. Among authors: ciferska h. Curr Rheumatol Rev. 2013;9(1):34-44. doi: 10.2174/1573397111309010009. Curr Rheumatol Rev. 2013. PMID: 25198366
High mobility group box-1 (HMGB-1) in osteoarthritic cartilage.
Heinola T, Kouri VP, Clarijs P, Ciferska H, Sukura A, Salo J, Konttinen YT. Heinola T, et al. Among authors: ciferska h. Clin Exp Rheumatol. 2010 Jul-Aug;28(4):511-8. Epub 2010 Aug 30. Clin Exp Rheumatol. 2010. PMID: 20659415
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
Smolen JS, Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Lee Y, Rho YH. Smolen JS, et al. Among authors: ciferska h. Ann Rheum Dis. 2018 Feb;77(2):234-240. doi: 10.1136/annrheumdis-2017-211741. Epub 2017 Oct 17. Ann Rheum Dis. 2018. PMID: 29042358 Free PMC article. Clinical Trial.
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
Smolen JS, Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Choi J, Rho YH. Smolen JS, et al. Among authors: ciferska h. Rheumatology (Oxford). 2017 Oct 1;56(10):1771-1779. doi: 10.1093/rheumatology/kex254. Rheumatology (Oxford). 2017. PMID: 28957563 Free PMC article. Clinical Trial.
21 results